Edition:
United States

Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

26.00USD
12 Dec 2017
Change (% chg)

$0.79 (+3.13%)
Prev Close
$25.21
Open
$25.32
Day's High
$26.92
Day's Low
$25.32
Volume
151,907
Avg. Vol
66,253
52-wk High
$26.92
52-wk Low
$7.14

Latest Key Developments (Source: Significant Developments)

Concert Pharmaceuticals reports Q3 earnings per share $5.61
Thursday, 9 Nov 2017 07:00am EST 

Nov 9 (Reuters) - Concert Pharmaceuticals Inc :Concert Pharmaceuticals reports third quarter 2017 financial results and provides company update.Q3 earnings per share $5.61.Q3 revenue $143.8 million.Q3 revenue view $11,700 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.54 -- Thomson Reuters I/B/E/S.Concert Pharmaceuticals Inc - ‍Expects cash, cash equivalents and investments as of September 30, 2017 to be sufficient to fund company into 2021​.  Full Article

Concert Pharmaceuticals announces completion of enrollment in First Cohort of CTP-543 phase 2a trial
Monday, 6 Nov 2017 07:00am EST 

Nov 6 (Reuters) - Concert Pharmaceuticals Inc :Concert Pharmaceuticals Inc announces completion of enrollment in First Cohort of CTP-543 phase 2a trial.Concert Pharmaceuticals Inc - ‍phase 2a trial on track to complete in second half of 2018​.  Full Article

Concert Pharma Says PTAB denies Incyte petition challenging CTP-543 patent
Thursday, 19 Oct 2017 01:00pm EDT 

Oct 19 (Reuters) - Concert Pharmaceuticals Inc ::Concert Pharma says patent trials and appeal board of u.s. patent and trademark office has denied Incyte's petition to institute IPR​.  Full Article

Concert Pharma pays total of $30.8 mln to Hercules Capital
Friday, 8 Sep 2017 07:38am EDT 

Sept 8 (Reuters) - Concert Pharmaceuticals Inc ::Concert Pharmaceuticals- ‍on Sept 7, paid total of $30.8 million to hercules capital outstanding under loan and security agreement with Hercules dated June 8.Concert Pharmaceuticals-upon payment of $30.8 million outstanding indebtedness, obligations of co owed to hercules were paid in full​.  Full Article

Concert Pharmaceuticals reports Q2 loss per share $0.58
Tuesday, 8 Aug 2017 07:00am EDT 

Aug 8 (Reuters) - Concert Pharmaceuticals Inc :Concert Pharmaceuticals reports second quarter 2017 financial results and provides company update.Q2 loss per share $0.58.Q2 earnings per share view $-0.66 -- Thomson Reuters I/B/E/S.Concert Pharmaceuticals Inc - ‍company believes pro forma cash will be sufficient to fund company into 2021​.  Full Article

Concert Pharmaceuticals terminates Hart-Scott-Rodino act waiting period for CTP-656 asset purchase agreement
Monday, 24 Jul 2017 07:00am EDT 

July 24 (Reuters) - Concert Pharmaceuticals Inc :Concert Pharmaceuticals announces termination of the Hart-Scott-Rodino act waiting period for CTP-656 asset purchase agreement with Vertex.Expiration of Hart-Scott-Rodino act waiting period represents final regulatory closing condition required to complete asset purchase.Termination for pending sale of CTP-656 and other assets related to treatment of cystic fibrosis by Concert to Vertex Pharmaceuticals.  Full Article

Concert Pharma says FDA lifts clinical hold on its clinical trial with CTP-543
Monday, 10 Jul 2017 07:30am EDT 

July 10 (Reuters) - Concert Pharmaceuticals Inc :Fda lifts clinical hold on concert pharmaceuticals clinical trial with ctp-543.Concert pharmaceuticals inc - ‍concert to resume enrollment in modified phase 2a trial for alopecia areata​.Concert pharmaceuticals inc - ‍company will amend protocol for phase 2a trial to evaluate two doses of ctp-543​.Concert pharmaceuticals inc - ‍expects to complete phase 2a trial second half of 2018​.  Full Article

Concert pharmaceuticals announces $30 million venture debt financing from hercules capital
Monday, 12 Jun 2017 07:00am EDT 

June 12 (Reuters) - Concert Pharmaceuticals Inc :Concert pharmaceuticals announces $30 million venture debt financing from Hercules Capital.Continue to expect to realize $160 million in connection with closing of CTP-656 asset purchase agreement with Vertex Pharmaceuticals.Debt is in form of a secured loan, secured by concert's assets, excluding intellectual property, and bearing interest of 8.55 pct.Loan will mature on June 1, 2021.  Full Article

Concert Pharmaceuticals announces departure of CFO, Ryan Daws
Tuesday, 30 May 2017 07:00am EDT 

May 30 (Reuters) - Concert Pharmaceuticals Inc ::Concert Pharmaceuticals announces departure of chief financial officer, Ryan Daws.Concert Pharmaceuticals Inc - concert has initiated a search to appoint a new CFO.Concert Pharmaceuticals - Daws will continue to consult with co, including through closing of pending asset purchase agreement with vertex pharmaceuticals, inc.  Full Article

Vertex Pharmaceuticals says FTC requested for additional information on pending acquisition from Concert Pharmaceuticals
Monday, 22 May 2017 08:07am EDT 

May 22 (Reuters) - Concert Pharmaceuticals Inc :Vertex Pharmaceuticals says on May 19, the U.S. FTC issued a request for additional information in connection co's pending acquisition of CTP-656 and other assets from Concert Pharmaceuticals.The second request was issued under notification requirements of the Hart-Scott-Rodino antitrust improvements act.Vertex Pharmaceuticals says it intends to work cooperatively with the FTC as it reviews the transaction.  Full Article

BRIEF-Concert Pharmaceuticals reports Q3 earnings per share $5.61

* Concert Pharmaceuticals reports third quarter 2017 financial results and provides company update